Eli Lilly's antibody drug for COVID-19 patients fails in study

Posted Oct 27, 2020 by Karen Graham
Late on Monday, the National Institute of Allergy and Infectious Diseases (NIAID), ended a study into the effectiveness of Eli Lilly's antibody treatment for hospitalized COVID-19 patients due to a lack of effectiveness.
It can take up to 90 days to manufacture a single batch of the active pharmaceutical ingredient and ...
It can take up to 90 days to manufacture a single batch of the active pharmaceutical ingredient and drug product for a neutralizing antibody for COVID-19. This is due to the highly complex manufacturing processes, with carefully controlled conditions and numerous quality and safety checks.
Eli Lilly and Company
Eli Lilly's drug trial is for its monoclonal antibody treatment that is used in combination with the anti-viral, remdesivir was paused two weeks ago after federal inspectors found serious quality control problems at an Eli Lilly and Co. pharmaceutical plant in Branchburg, New Jersey.
However, late on Monday, according to The Hill, NIAID = which is funding the study - announced that an independent monitoring board found little clinical benefit in the treatment, and recommended that it be stopped.
NBC News is saying the termination of the Lilly study poses a real setback for the promising antibody treatment. President Donald Trump received a similar treatment using Regeneron's antibody treatment while he was hospitalized with the coronavirus earlier this month.
Trump ally and former New Jersey Governor Chris Christie said he was treated with Lilly's antibody-drug, along with remdesivir. Christie is just one of about 30 people who contracted the coronavirus at the White House over the past several weeks.
NIAID said on Monday that while Lilly's monoclonal antibody treatment study has been halted, it plans to test other experimental drugs as COVID-19 treatments in the study.
Eli Lilly said Monday that all other studies of its monoclonal antibody drug, bamlanivimab, will continue, including one in recently diagnosed COVID-19 patients with mild to moderate symptoms and another in people at risk of infection, reports ABC News.
"While there was insufficient evidence that bamlanivimab improved clinical outcomes when added to other treatments in hospitalized patients with COVID-19, we remain confident based on data from Lilly’s BLAZE-1 study that bamlanivimab monotherapy may prevent progression of the disease for those earlier in the course of COVID-19," Eli Lilly and Company said in a statement Monday.